IMS Monthly Market Reflection Report
Wednesday, April 1, 2026
22.3
C
Bengaluru
Hot topics
Mounjaro to Orforglipro: Lilly’s $6 Billion Bet on the Next GLP‑1 Revolution
Eli Lilly is in a rare position. Its GLP-1...
DigiStorm 2018: Intent, Content, Strategy and Skills
The pharma industry in India is entering a very interesting variant of the post-digital marketing era. The term “post-digital marketing” is used to depict a state where the lines between physical and digital blur considerably for a customer. However, in the context of pharma, this means a state where the industry has stopped questioning the need for digital and has begun to implement very interesting digital marketing initiatives.
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Violence Against Medics – Lessons to Draw from Private Hospitals
One interesting fact: most medical colleges and linked public hospitals in major cities were designed in the British era, with an open ward design. A medical administrator, tongue-in-cheek, put it succinctly: “When these hospitals were designed, nobody would have imagined that doctors will face violence”.
Time for design thinking in public healthcare delivery!
Alok Sonig Appointed CEO of Rosemont Pharmaceuticals
Effective January 1, 2026, Rosemont Pharmaceuticals has announced the...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Hot topics
Astra Zeneca Tops Indian Pharma in New Introductions 2024
Analysis of Indian Pharmaceutical Market (IPM) – 2024
This data...
The Semaglutide Story: How One Molecule Re‑wired Obesity, Patents and Pharma Profits
1. From Gut Hormone to “Wonder Drug”
If you strip...
Breaking Performance Barriers
Articles by K. Hariram, Pankaj Mehrotra, Rinkesh Shah, Gopal Kishore, Amaninder S. Dhillon, Ramandish Arora, Mohit Kumar Bhutani, Richa Goyal, and Mahendra Kumar Rai
The Pill is Now a Commodity – Can ‘Beyond the Pill’ Models Work in India?
The pill is now a commodity that many of these companies provide at heavy discounts, making money off everything ‘beyond the pill’. Investors are betting heavily on the potential of technological innovation to transform the way healthcare is delivered.
The Economic Times reported that in 2021, India recorded investments of $77 billion across 1,266 deals including 164 large deals worth $58 billion. While the money reduced in 2022, the reason wasn’t a lack of faith in this business model.
Meanwhile, the pharmaceuticals industry that is most affected by this quiet but rapid change, is grappling with its entrenched culture. Its current business is so profitable that everything else pales in comparison.
‘Build, measure, learn, build again’ – a mantra of the health tech industry is alien to pharma that doesn’t learn, build or measure after launching a product.
Pharma also thinks of its customers as doctors alone and does precious little to connect with patients, or caregivers. People who are not sick do not feature on their radar at all. These are cultural values that keep pharma focused on the pill and discourage thinking beyond it.
A social media poll conducted by MedicinMan showed almost predictable responses. 100+ respondents who work in the pharma industry in India were quite clearly divided. 48% of them wanted to know what beyond the pill actually meant, while 23% wanted to know how to execute it.
The rest felt that the ultra-competitive environment in the Indian generics market required very high share-of-voice tactics (19%), or that their customers demanded product information (9%).
Interview with Ajit Singh, Chairman, ACG
Special interview with the Chairman of ACG and an invitation to "Pharmaceutical Marketing in the New Age" - a conference presented by ACG in partnership with MedicinMan
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
Abstract
When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
As over 50 generic versions of the blockbuster weight-loss...
Newsletter
Get important news delivered directly to your inbox and stay connected!